**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 52497

**Manuscript Type:** ORIGINAL ARTICLE

***Randomized Controlled Trial***

**Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone *vs* placebo for the treatment of patients with post-traumatic stress disorder and insomnia**

Dowd SM *et al*. Eszopiclone for PTSD and insomnia

Sheila M Dowd, Alyson K Zalta, Helen J Burgess, Elizabeth E Adkins, Zerbrina Valdespino-Hayden, Mark H Pollack

**Sheila M Dowd**, **Mark H Pollack,** Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL 60601, United States

**Alyson K Zalta,** Department of Psychological Science, University of California Irvine, Irvine, CA 92697, United States

**Helen J Burgess,** Sleep and Circadian Research Laboratory, Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, United States

**Elizabeth E Adkins,** Center for Behavioral Intervention Technologies | Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States

**Zerbrina Valdespino-Hayden,** Department of Psychology, Montclair State University, Montclair, NJ 07043, United States

**Author contributions:** Pollack MH designed the research; Pollack MH, Dowd SM, Zalta AK, Adkins EE and Valdespino-Hayden Z performed the research; Valdespino-Hayden Z and Burgess HJ scored and analyzed the sleep data; Pollack MH, Dowd SM, Zalta AK, Burgess HJ, Adkins EE and Valdespino-Hayden Z wrote the paper.

**Supported by** National Institute of Mental Health, No. 5R34MH91338-03 and No. K23 MH103394 (to Zalta AK).

**Corresponding author:** **Sheila M Dowd, PhD, Associate Professor,** Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd Suite 400, Chicago, IL 60601, United States. [sheila\_dowd@rush.edu](mailto:sheila_dowd@rush.edu)

**Received:** November 13, 2019

**Revised:** February 10, 2020

**Accepted:** February 23, 2020

**Published online:**

**Abstract**

BACKGROUND

Sleep disturbance is a core feature of post-traumatic stress disorder (PTSD). Given the relationship between sleep disturbance and PTSD, there has been a relative paucity of studies examining the potential therapeutic impact of using pharmacotherapy to target sleep disturbance in patients with PTSD. Eszopiclone (ESZ) is a non-benzodiazepine y-aminobutyric acid-A receptor agonist indicated for the treatment of sleep and may affect sleep in patients with PTSD.

AIM

To evaluate the efficacy of ESZ *vs* placebo (PBO) for patients with PTSD and insomnia.

METHODS

The study was a 12-wk, double blind, randomized controlled trial with 3 mg of ESZ (*n* = 13) or PBO (*n* = 12).

RESULTS

Patients in both arms experienced significant improvement in PTSD symptoms as assessed by the Clinician-Administered PTSD Scale for DSM-IV (CAPS): ESZ (t11 = -3.12, *P* = 0.005) and PBO (t11 = -3.5, *P* = 0.002) and by self-report with the Short PTSD Rating Interview (ESZ t11 = -3.38, *P* = 0.003 and PBO t11 = -4.48, *P* = 0.0005). There were no significant differences between treatments on the CAPS (t22 = -0.13, *P* = 0.70) or the Short PTSD Rating Interview (t22 = -0.58, *P* = 0.56). Similarly, both treated groups improved on sleep measures as assessed by the Pittsburgh Sleep Quality Index with PTSD Addendum (PSQI) and on total sleep time (TST) and sleep latency assessed by actigraphy with no significant differences between groups (PSQI t22 = -0.24, *P* = 0.81; total sleep time t10 = 0.13, *P* = 0.90 and sleep latency t10 = 0.68, *P* = 0.50). There was a significant correlation between improvement in sleep and overall improvement in PTSD as measured by change scores on the PSQI and CAPS, r(8) = 0.79, *P* = 0.01 for ESZ treated subjects, but not for those treated with PBO r(9) = 0.16, *P* = 0.69. Adverse events of ESZ were consistent with the known profile of the medication including dysgeusia (30%, mild), sedation (20%, mild) and headache (20%, moderate to severe).

CONCLUSION

Results do not support the hypothesis of a specific positive effect of ESZ compared to PBO for measures of PTSD and associated sleep disturbance.

**Key words**: Trauma; Sleep disturbance; Hypnotic; Post-traumatic stress disorder

Dowd SM, Zalta AK, Burgess HJ, Adkins EE, Valdespino-Hayden Z, Pollack MH. Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone *vs* placebo for the treatment of patients with post-traumatic stress disorder and insomnia. *World J Psychiatr* 2020; In press

**Core tip:**  Sleep disturbance is a core feature of post-traumatic stress disorder (PTSD) yet few studies have examined the impact of psychopharmacotherapy. Results from this randomized controlled parallel study in individuals with PTSD and sleep disturbance did not demonstrate a significant relative improvement for eszopiclone (ESZ) *vs* placebo treated patients. Although patients receiving ESZ did experience significant improvement in measures of PTSD and sleep disturbance, placebo treated patients also significantly improved on these outcomes. Thus the potential role for ESZ in the treatment of PTSD remains uncertain until a larger more definitive trial is undertaken.

**INTRODUCTION**

Sleep disturbance is a core feature of post-traumatic stress disorder (PTSD) and is reported by 70%-91% of patients with PTSD in civilian and combat veteran populations[1]. Dysregulated sleep is associated with a number of adverse consequences and in the aftermath of trauma exposure is a marker and perhaps risk factor for the development of PTSD or may contribute to its persistence[2-4]. Disturbed sleep among individuals with PTSD is associated with measures of poorer clinical status including depression and suicidality, poorer perceived physical health and somatization and increased rates of alcohol and substance use, and decreased overall quality of life and functioning[3,5-7]. In addition, sleep deprivation in preclinical studies led to impaired extinction learning in fear conditioned rats, a possible explanation for the impact of sleep disturbance a finding of potential relevance in explaining the persistence of PTSD in individuals with ongoing sleep disturbance[8].

Given the relationship between sleep disturbance and PTSD, there has been a relative paucity of studies examining the potential therapeutic impact of using pharmacotherapy to target sleep disturbance in patients with PTSD. Serotonin reuptake inhibitors including selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors are commonly used to treat PTSD. Sertraline and paroxetine are Food and Drug Administration approved for this indication however they were found to either worsen sleep disturbance or sleep was not assessed in individuals with PTSD[9]. The antidepressant trazodone, often used in low doses to treat insomnia, was reported effective for the treatment of PTSD as well as sleep disturbance in a small open trial[10]. Prazosin, an α1-adrenergive receptor antagonist was found to be beneficial in reducing trauma related nightmares and overall global illness in several placebo (PBO) controlled trials in military and civilian PTSD patients[11]. A related compound, α-1 adrenergic antagonist doxazosin has been reported useful for PTSD related sleep disturbance in an open trial and also demonstrated efficacy in a randomized controlled trial of the extended release formulation for PTSD related sleep disturbance and overall PTSD symptoms[12,13]. Alternatively, studies of psychotherapy interventions found improvement in sleep quality and symptoms of PTSD. In a randomized controlled trial of sexual assault survivors using Imagery Rehearsal therapy a modified Cognitive Behavioral Therapy technique focused on sleep education, changing an aspect of a nightmare and rehearsing it daily, there was significant improvement in nightmares, sleep quality and overall PTSD symptoms[14,15].

Benzodiazepines are often used in the treatment of PTSD because of their anxiolytic and hypnotic effects. One clinical trial with alprazolam demonstrated no significant benefit for PTSD, and a small PBO controlled trial of clonazepam for PTSD-related sleep disturbance, reported no significant benefit for the benzodiazepine[16,17]. Treatment guidelines discourage the use of benzodiazepines in the treatment of PTSD because of lack of demonstrated efficacy, concerns related to abuse and dependence, and potential adverse impact on exposure based cognitive-behavioral therapy[18]. Among the non-benzodiazepine y-aminobutyric acid-A receptor agonist hypnotics several case reports of veterans treated with the hypnotic zolpidem showed improvement in PTSD associated insomnia[19].

Eszopiclone (ESZ) is a non-benzodiazepine y-aminobutyric acid-A receptor agonist indicated for the treatment of sleep onset and maintenance[20]. In addition to effects on primary insomnia, ESZ has been studied as augmentation to selective serotonin reuptake inhibitors for the treatment of major depression and generalized anxiety disorder[21,22]. In a small 7-wk crossover study, 3 wk of ESZ was associated with short-term improvement in overall PTSD severity as well as sleep disturbance[23]. In the present report, we present findings from a 12 wk randomized parallel PBO controlled trial to evaluate the relative efficacy, safety and tolerability of ESZ and PBO for the treatment of PTSD and associated sleep disturbance.

**MATERIALS AND METHODS**

The study was a 12-wk, double blind, randomized controlled trial with 3 mg of ESZ or PBO at bedtime with a one-month follow-up visit. Investigators were blind to the randomization sequence, which was designed by the Medical Center’s research pharmacy. Recruitment began in September of 2012 and completed in 2015. Randomization was stratified by symptom severity as measured by a Clinician-Administered PTSD Scale for DSM-IV score of > 75 (CAPS)[24]. Safety evaluations, included assessment of medication use and drug allergies, and laboratory results (CBC, chemistry, pregnancy, thyroid function, EKG, urine toxicology screen and urinalysis). A study physician performed a medical history and physical exam and evaluated lab results to rule out excluded medical conditions. Diagnosis was determined with the Structured Clinical Interview for the DSM-IV[25].

The primary outcome measure to assess for efficacy for PTSD symptomatology was change in CAPS, which was assessed six times throughout the study. The CAPS is a 30-item, structured interview assessing the presence and severity of the DSM-IV PTSD criteria with demonstrated validity and reliability. The primary outcome measure for efficacy on sleep symptomatology was change in the Pittsburgh Sleep Quality Index with PTSD Addendum (PSQI), which was administered weekly[26].The PSQI with PTSD Addendum is a 13-item, well-validated and reliable patient administered scale with higher scores reflecting poorer sleep.

The secondary outcome measures included the: (1) Short PTSD Rating Interview (SPRINT) to assess for PTSD symptomatology, a 10-item, valid and reliable clinician-administered scale assessing core and related symptoms of PTSD collected weekly; (2) self-report sleep diary to assess for change in insomnia including sleep latency and total sleep time recorded daily for 12 wk; and (3) actigraphy to assess for change in sleep, including total sleep time, initial insomnia and number of awakenings[27]. Actigraphy data was collected daily for the week between baseline and week 1 as well as between week 11 and week 12. Additional clinician-rated instruments included a measure of depression and global clinical severity with the Montgomery-Asberg Depression Rating Scale, and the Clinical Global Impression Scale[28,29]. A measure of global functioning was also completed using the Range of Impaired Functioning Tool (LIFE-RIFT)[30].

***Inclusion and exclusion criteria***

Subjects included male and female outpatients, aged 18-65 years of age with a primary DSM-IV diagnosis of PTSD and confirmed with CAPS score of > 45. Associated sleep disturbance was operationalized as (1) positive score on diagnostic criterion item D1: “difficulty falling or staying asleep”; (2) sleep latency > 30 min; and (3) total sleep time < 6.5 h at least three times per week over the previous month. A lifetime history of psychotic disorders was exclusionary, as was a history of alcohol/substance abuse in the last 3 mo. Concurrent use of antidepressants or benzodiazepines (on a stable dose for at least 6 wk) was allowed. Patients receiving current psychotherapy initiated within 3 mo of randomization or ongoing psychotherapy of any duration directed specifically toward treatment of PTSD and/or sleep disturbance (*e.g*., CBT) were excluded, but general supportive individual, couple/family therapy > 3 mo duration was permitted. Patients who had current legal actions related to trauma or an ongoing relationship with their assailant were also excluded.

***Informed consent***

Informed consent was obtained prior to the initial assessment. The study was approved by the Institutional Review Board of Rush University Medical Center and was registered on ClinicalTrials.gov (Identifier: NCT01605253).

***Statistics***

The primary analysis used last observation carried forward approach in a modified intent to treat population that excluded subject who did not receive at least 1 dose of study drug. Baseline to endpoint (week 12) change scores were examined on the primary and secondary measures. All tests were 2-tailed with significance set at an α of 0.05. Correlations were completed comparing change scores on scales measuring sleep and PTSD.

**RESULTS**

There were no significant differences in demographics between groups at baseline. Of the 25 randomized subjects (13 ESZ, 12 PBO) 9 did not complete the study (ESZ = 6, PBO = 3). Four experienced worsening symptoms (2 ESZ, 2 PBO), 1 had memory disturbance (ESZ) and 4 were lost to follow up (3 ESZ, 1 PBO). Baseline demographics and clinical characteristics of the 25 randomized patients are presented in Table 1. The nature of the traumas included sexual assault or abuse (*n* = 6), physical abuse or assault (*n* = 6), observed violence to or death of a loved one (*n* = 3), military combat related trauma (*n* = 1), medical trauma (*n* = 2), car accident (*n* = 5), fire (*n* = 1) and accident (*n* = 1). A complete set of actigraphy data was obtained on a total of 12 subjects, 6 in the ESZ group and 6 in the PBO group. Only three subjects received concomitant medication, all in the PBO group, 2 received an antidepressant and 1 a benzodiazepine.

***PTSD assessments***

In the last observation carried forward, both treatment groups experienced significant improvement on the CAPS, (ESZ t11 = -3.12, *P* = 0.005 and PBO t11 = -3.5, *P* = 0.002) and the SPRINT (ESZ t11 = -3.38, *P* = 0.003 and PBO t11 = -4.48, *P* = 0.0005) (Table 2). However, there was no significant difference in outcome for ESZ *vs* PBO treated patients as reflected by the CAPS (t22 = -0.13, *P* = 0.70) nor the SPRINT (t22 = -0.58, *P* = 0.56). In a post-hoc analysis to determine if the core symptoms of PTSD were improved apart from effects on specific sleep symptoms, analyses were performed after removing the sleep items on the CAPS (item B2 and D1). There were no significant treatment effects for the remaining PTSD items of the CAPS (t22 = 0.25, *P* = 0.81).

***Sleep assessments***

There were no significant differences between ESZ and PBO on changes in the total score of the PSQI (t22 = -0.24, *P* = 0.81). Of the 12 subjects with complete actigraphy data, changes in total sleep time and latency were also not significantly different between ESZ and PBO (t10 = 0.13, *P* = 0.90 and t10 = 0.68, *P* = 0.50, respectively), consistent with results from the self-reported Total Sleep Time and Latency as assessed by the PSQI. In those treated with ESZ, there was a correlation between improvement in sleep and overall improvement in PTSD as measured by change scores on the PSQI and CAPS, r(8) = 0.79, *P* = 0.019. This was not true for those treated with PBO r(9) = 0.16, *P* = 0.69.

There was a correlation between the PSQI improvement and SPRINT improvement but this is the case only for the ESZ group r(8) = 0.89, *P* = 0.002 and not PBO at week 12 r(9) = 0.58, *P* = 0.10. In addition, there was a correlation in the ESZ group with improvement on TST with improvement on the SPRINT r(8) = -0.71, *P* = 0.05 but again, not in the PBO group r(9) = -0.51, *P* = 0.16.

***Additional assessments***

There were no significant differences in between ESZ and PBO change scores on the MADRAS (t22 = -0.73, *P* = 0.47) and the Clinical Global Impression - Severity Scale (t22 = 1.00, *P* = 1.00). Total change scores on the Range of Impaired Functioning Tool were also not significantly different between the two groups (t22 = 0.916, *P* = 0.369).

***Adverse events***

The most common adverse events experienced by subjects receiving ESZ were consistent with the known side effect profile for the drug and included dysgeusia (30%, mild), sedation (20%, mild) and headache (20%, moderate to severe). Adverse events in the subjects receiving PBO included most commonly dysgeusia (25%, mild) and a change in urine color or smell (25%, mild). Other adverse events in the PBO group included headache (16%, mild) and dry mouth (16%, mild). In order to enhance blinding, a trace amount of vitamin B was added to the PBO capsule, which may have contributed to some of these reported adverse events however was unlikely to affect sleep.

**DISCUSSION**

Results from this randomized controlled parallel study in individuals with PTSD and sleep disturbance did not demonstrate a significant relative improvement for ESZ *vs* PBO treated patients. Although patients receiving ESZ did experience significant improvement in measures of PTSD and sleep disturbance, PBO treated patients also significantly improved on these outcomes. Of note, improvement in PTSD symptoms as assessed by both clinician and self-reports for the ESZ but not PBO treated patients was correlated with improvements in sleep suggesting the potential importance of this specific association for the active treatment *vs* PBO effect. Potential reasons for the negative findings in this study include the significant positive response of the PBO treated patients, the greater amounts of drop out amongst the ESZ *vs* PBO treated patients (50% *vs* 25%), and higher rates of past alcohol and substance abuse in the ESZ treated patients (62% *vs* 25%) with these latter two factors approaching but not achieving statistical significance given the small sample size.

This overall finding was in contrast to a report from an earlier small (*n* = 24) randomized PBO controlled crossover study with ESZ that demonstrated significant positive effects on PTSD and sleep for ESZ relative to PBO[22]. However, in that study, response to PBO was minimal, rate of drop out for both treatment groups was 7%, and the rates of past alcohol and substance abuse was lower (37%) than for ESZ treated patients in the current study.

Thus the potential role for ESZ in the treatment of PTSD remains uncertain until a larger more definitive trial is undertaken. In addition to the current negative study, a recent 26 wk multi-centered, double-blind PBO controlled study of prazosin in veterans from 13 Veterans Affairs Medical Centers found no benefit for the active agent over PBO or overall PTSD symptomatology[31].The data from insomnia focused CBT appears to improve sleep but no other symptoms of PTSD. However, the data from Imagery Rehearsal therapy for the treatment of PTSD is positive, suggesting a therapeutic role for affected patients[15]. Thus, further work is necessary to establish the potential role and patient population of sleep disturbance targeted pharmacotherapy for the treatment of patients with PTSD.

**ARTICLE HIGHLIGHTS**

***Research background***

Sleep disturbance is a frequent concern and an important component of post-traumatic stress disorder (PTSD). It is associated with several adverse consequences and may be a marker and risk factor for developing PTSD. It is also possible that it contributes to the difficulty treating PTSD. Preclinical studies have found impaired extinction learning in fear conditioned rates, a possible explanation for the impact of sleep disturbance.

***Research motivation***

There are few studies focused on the use of pharmacotherapy targeting sleep disturbance. However there is evidence that sleep disturbance among patients with PTSD are associated with increased rates of depression, suicidal ideation, increased use of alcohol and substances and poorer functioning.

***Research objectives***

The main objective was to examine the possible benefits of eszopiclone on sleep disturbance in PTSD.

***Research methods***

The study was a randomized controlled parallel study of participants with PTSD and sleep disturbance. We collected both self-report and clinician administered measures of PTSD and sleep quality. In addition, actigraphy data were collected and compared to patient’s self-report sleep logs.

***Research results***

The study did not find a significant relative improvement for those treated with eszopiclone compared to placebo. Those participants receiving eszopiclone experienced significant improvement in symptoms of PTSD and sleep disturbance, as did the participants receiving placebo. However, clinician and self-report measures of PTSD were correlated with improvement in sleep for the eszopiclone, but not placebo-treated patients, suggesting the potential importance of this specific association for the active treatment *vs* placebo effect. Interestingly, there were greater amounts of dropouts amongst the eszopiclone *vs* placebo treated patients. In addition, there were higher rates of past alcohol and substance abuse in the eszopiclone treated patients with two factors approaching, but not achieving statistical significance. Due to the small sample size, the potential role for eszopiclone in the treatment of PTSD remains uncertain until a larger more definitive trial is undertaken

***Research conclusions***

The findings of this study have contributed to the mixed evidence exploring pharmacotherapy in the treatment of sleep disturbance in patients with PTSD.

***Research perspectives***

Further work is needed to determine the potential role for pharmacotherapy targeting sleep disturbance in patients with PTSD.

**REFERENCES**

1 **Maher MJ**, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. *CNS Drugs* 2006; **20**: 567-590 [PMID: 16800716 DOI: 10.2165/00023210-200620070-00003]

2 **Bryant RA**, Creamer M, O'Donnell M, Silove D, McFarlane AC. Sleep disturbance immediately prior to trauma predicts subsequent psychiatric disorder. *Sleep* 2010; **33**: 69-74 [PMID: 20120622 DOI: 10.1093/sleep/33.1.69]

3 **Wright KM**, Britt TW, Bliese PD, Adler AB, Picchioni D, Moore D. Insomnia as predictor versus outcome of PTSD and depression among Iraq combat veterans. *J Clin Psychol* 2011; **67**: 1240-1258 [PMID: 22065464 DOI: 10.1002/jclp.20845]

4 **Giosan C**, Malta LS, Wyka K, Jayasinghe N, Evans S, Difede J, Avram E. Sleep disturbance, disability, and posttraumatic stress disorder in utility workers. *J Clin Psychol* 2015; **71**: 72-84 [PMID: 25099348 DOI: 10.1002/jclp.22116]

5 **Saladin ME**, Brady KT, Dansky BS, Kilpatrick DG. Understanding comorbidity between PTSD and substance use disorders: two preliminary investigations. *Addict Behav* 1995; **20**: 643-655 [PMID: 8712061 DOI: 10.1016/0306-4603(95)00024-7]

6 **Nishith P**, Resick PA, Mueser KT. Sleep difficulties and alcohol use motives in female rape victims with posttraumatic stress disorder. *J Trauma Stress* 2001; **14**: 469-479 [PMID: 11534879 DOI: 10.1023/A:1011152405048]

7 **Krakow B**, Melendrez D, Johnston L, Warner TD, Clark JO, Pacheco M, Pedersen B, Koss M, Hollifield M, Schrader R. Sleep-disordered breathing, psychiatric distress, and quality of life impairment in sexual assault survivors. *J Nerv Ment Dis* 2002; **190**: 442-452 [PMID: 12142845 DOI: 10.1097/00005053-200207000-00004]

8 **Silvestri AJ**. REM sleep deprivation affects extinction of cued but not contextual fear conditioning. *Physiol Behav* 2005; **84**: 343-349 [PMID: 15763570 DOI: 10.1016/j.physbeh.2004.11.011]

9 **Brownlow JA**, Harb GC, Ross RJ. Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature. *Curr Psychiatry Rep* 2015; **17**: 41 [PMID: 25894359 DOI: 10.1007/s11920-015-0587-8]

10 **Hertzberg MA**, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. *J Clin Psychopharmacol* 1996; **16**: 294-298 [PMID: 8835704 DOI: 10.1097/00004714-199608000-00004]

11 **Khachatryan D**, Groll D, Booij L, Sepehry AA, Schütz CG. Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. *Gen Hosp Psychiatry* 2016; **39**: 46-52 [PMID: 26644317 DOI: 10.1016/j.genhosppsych.2015.10.007]

12 **De Jong J**, Wauben P, Huijbrechts I, Oolders H, Haffmans J. Doxazosin treatment for posttraumatic stress disorder. *J Clin Psychopharmacol* 2010; **30**: 84-85 [PMID: 20075659 DOI: 10.1097/JCP.0b013e3181c827ae]

13 **Rodgman C**, Verrico CD, Holst M, Thompson-Lake D, Haile CN, De La Garza R 2nd, Raskind MA, Newton TF. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. *J Clin Psychiatry* 2016; **77**: e561-e565 [PMID: 27249080 DOI: 10.4088/JCP.14m09681]

14 **Krakow B**, Hollifield M, Johnston L, Koss M, Schrader R, Warner TD, Tandberg D, Lauriello J, McBride L, Cutchen L, Cheng D, Emmons S, Germain A, Melendrez D, Sandoval D, Prince H. Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. *JAMA* 2001; **286**: 537-545 [PMID: 11476655 DOI: 10.1001/jama.286.5.537]

15 **Casement MD**, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: effects on nightmare frequency, sleep quality, and posttraumatic stress. *Clin Psychol Rev* 2012; **32**: 566-574 [PMID: 22819998 DOI: 10.1016/j.cpr.2012.06.002]

16 **Braun P**, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. *J Clin Psychiatry* 1990; **51**: 236-238 [PMID: 2189869 DOI: 10.1016/0165-0327(90)90020-9]

17 **Cates ME**, Bishop MH, Davis LL, Lowe JS, Woolley TW. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. *Ann Pharmacother* 2004; **38**: 1395-1399 [PMID: 15252193 DOI: 10.1345/aph.1E043]

18 **United States** **Department of Veterans Affairs**, Department of Defense. VA/DoD clinical practice guideline for management of post-traumatic stress (PTSD). Available from: https://www.healthquality.va.gov/

19 **Dieperink ME**, Drogemuller L. Zolpidem for insomnia related to PTSD. *Psychiatr Serv* 1999; **50**: 421 [PMID: 10096658 DOI: 10.1176/ps.50.3.421]

20 **Sateia MJ**, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med* 2017; **13**: 307-349 [PMID: 27998379 DOI: 10.5664/jcsm.6470]

21 **Fava M**, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. *Biol Psychiatry* 2006; **59**: 1052-1060 [PMID: 16581036 DOI: 10.1016/j.biopsych.2006.01.016]

22 **Pollack M**, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. *Arch Gen Psychiatry* 2008; **65**: 551-562 [PMID: 18458207 DOI: 10.1001/archpsyc.65.5.551]

23 **Pollack MH**, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2011; **72**: 892-897 [PMID: 21367352 DOI: 10.4088/JCP.09m05607gry]

24 **Blake DD**, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. *J Trauma Stress* 1995; **8**: 75-90 [PMID: 7712061 DOI: 10.1007/bf02105408]

25 **First MB**, Spitzer RL, Gibbon M, [Williams](https://www.researchgate.net/profile/Janet_Williams2) JBW. Structured clinical interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, 1995

26 **Germain A**, Hall M, Krakow B, Katherine Shear M, Buysse DJ. A brief sleep scale for Posttraumatic Stress Disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. *J Anxiety Disord* 2005; **19**: 233-244 [PMID: 15533706 DOI: 10.1016/j.janxdis.2004.02.001]

27 **Connor KM**, Davidson JR. SPRINT: a brief global assessment of post-traumatic stress disorder. *Int Clin Psychopharmacol* 2001; **16**: 279-284 [PMID: 11552771 DOI: 10.1097/00004850-200109000-00005]

28 **Montgomery SA**, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; **134**: 382-389 [PMID: 444788 DOI: 10.1192/bjp.134.4.382]

29 **Guy W**. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health, 1976: 218-222

30 **Leon AC**, Solomon DA, Mueller TI, Endicott J, Posternak M, Judd LL, Schettler PJ, Akiskal HS, Keller MB. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool. *J Nerv Ment Dis* 2000; **188**: 805-812 [PMID: 11191580 DOI: 10.1097/00005053-200012000-00003]

31 **Raskind MA**, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, Hart KL, McFall M, Mellman TA, Reist C, Romesser J, Rosenheck R, Shih MC, Stein MB, Swift R, Gleason T, Lu Y, Huang GD. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. *N Engl J Med* 2018; **378**: 507-517 [PMID: 29414272 DOI: 10.1056/NEJMoa1507598]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of Rush University Medical Center.

**Clinical trial registration statement:** The study was registered on ClinicalTrials.gov. The registration identification number is NCT01605253.

**Informed consent statement:** Informed consent was obtained prior to the initial assessment.

**Conflict-of-interest statement:** Dr. Dowd reports grants from NIMH, during the conduct of the study; other from The Wellness Network, grants from Jansse Pharmaceuticals, grants from National Institutes of Health, outside the submitted work.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** November 13, 2019

**First decision:** January 15, 2020

**Article in press:**

**Specialty type:** Psychiatry

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Shiina A **S-Editor:** Yan JP **L-Editor:** **E-Editor:**

**Table 1 Baseline demographic and clinical characteristics of patient (*n* = 25)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Eszopiclone**  **(*n* = 13)** | **Placebo**  **(*n* = 12)** | **Total sample**  **(*n* = 25)** |
| Age, mean ± SD  Sex, male, *n* (%)  Race, *n* (%)  White  African American  Hispanic  Mixed  Education status, college graduate, *n* (%)  Duration of illness in years, mean ± SD  Current comorbidity, *n* (%)  Major depressive disorder  Social anxiety disorder  Generalized anxiety disorder  Lifetime depression, *n*  Lifetime alcohol or substance abuse or dependency, *n*  Concomitant antidepressant, *n*  Concomitant benzodiazepine, *n*  Drop-outs | 38 ± 11.6  8 (54)  4  7  1  1  5  5 ± 7  7  2  0  8  8  0  0  6 | 48 ± 11.3  7 (58)  2  7  1  2  4  7 ± 8  7  1  1  9  3  2  1  3 | 43 ± 12.2  15 (60)  6 (24)  14 (56)  2 (8  3 (12)  9 (36)  6 ± 8  14  3  1  17  11  2  1  9 |

**Table 2 Outcome measures – completers**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Eszopiclone** | | **Placebo** | |  |  |
| **Measure** | Baseline (mean ± SD) | Endpoint (mean ± SD) | Baseline (mean ± SD) | Endpoint (mean ± SD） | ***t* (*df*)** | ***P* value** |
| CAPS total score | 65 ± 22.04 | 40 ± 20.13 | 64 ± 10.93 | 41 ± 16.94 | -0.13 (22) | 0.70 |
| SPRINT total score | 22 ± 5.55 | 13 ± 6.58 | 24 ± 3.61 | 14 ± 4.79 | -0.58 (22) | 0.56 |
| PSQI total score | 12.58 ± 3.12 | 8.38 ± 3.35 | 12.33 ± 3.94 | 7.44 ± 2.31 | 0.24 (22) | 0.81 |
| Total sleep time | 6.75 ± 2.11 | 7.00 ± 1.82 | 6.15 ± 1.74 | 6.78 ± 1.26 | 0.13 (10) | 0.41 |
| Sleep latency | 31.11 ± 26.54 | 39.70 ± 48.16 | 44.06 ± 37.55 | 37.42 ± 26.27 | 0.68 (10) | 0.77 |
| MADRAS total score | 24.25 ± 7.28 | 18.33 ± 9.59 | 25.56 ± 9.46 | 21.00 ± 10.80 | 0.73 (22) | 0.47 |
| CGI severity | 4.42 ± 0.79 | 4.00 ± 0.95 | 4.50 ± 0.80 | 4.08 ± 0.79 | 0.00 (22) | 1.00 |
| LIFE-RIFT total score | 13.50 ± 2.64 | 11.92 ± 4.14 | 13.58 ± 2.87 | 12.83 ± 3.22 | 0.92 (22) | 0.37 |

CAPS: Clinician-Administered Post-Traumatic Stress Disorder Scale; SPRINT: Short Post-Traumatic Stress Disorder Rating Interview; PSQI: Pittsburgh Sleep Quality Index with Post-Traumatic Stress Disorder Addendum; CGI: Clinical Global Impression; LIFE-RIFT: Range of Impaired Functioning Tool.